Yestar Healthcare Holdings Company Limited announced that it expects to receive funding from Getein Biotech, Inc
April 07, 2022
Share
Yestar Healthcare Holdings Company Limited announced that it has entered into an investment letter of intent with Getein Biotech, Inc on April 8, 2022. As part of the transaction, investor will hold not less than 30% stake. The transaction has been approved in the 18th meeting of the company's 3rd directorate.
Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.
GETEIN BIOTECH, INC 
